NEUCHATEL, Switzerland, Oct. 24, 2023 /PRNewswire/ -- Aktiia SA, the world leader in cuffless blood pressure technology, is proud to announce its collaboration with the Genetic and phenotypic determinants of blood pressure and other cardiovascular risk factors (GAPP) study investigators, Professors David Conen MD MPH at McMaster University and Lorenz Risch MD MPH at the Private University of Liechtenstein and the Dr. Risch Laboratory.
The GAPP study, a large prospective cohort study in the Principality of Liechtenstein composed of more than 2000 participants followed for > 1 decade to determine the genetic and phenotypic factors for blood pressure and cardiovascular diseases, has chosen Aktiia's unique 24/7 Blood Pressure monitoring technology to play a key role in its ongoing research. This collaboration aims to unlock the links between longitudinal blood pressure patterns and genetic, biomarker, imaging, and healthcare data, paving the way for groundbreaking discoveries in the field.
Recognized as one of the foremost authorities in their respective fields, Professors David Conen at McMaster University and Lorenz Risch at the Private University of Liechtenstein and the Dr. Risch Laboratory have led the GAPP study since its launch in 2010 with a wealth of expertise and experience. Thanks to its highly qualified clinical site staff, the GAPP study has enabled to collect millions of data subjects and has already generated dozens of notable publications, contributing significantly to our understanding of blood pressure and cardiovascular risk factors.
As a pioneer in cuffless blood pressure monitoring, Aktiia is uniquely positioned to contribute valuable insights and data to the GAPP study, with little to no extra burden on the study participants. By leveraging their innovative technology, Aktiia has created a solution that captures an average of 27 blood pressure data points per day per participant, creating a novel blood pressure dataset and revolutionizing the way blood pressure is analyzed, understood, and optimized.
Including Aktiia's 24/7 technology in the GAPP study, the investigators aim to explore the additional value of continual blood pressure data associated with phenotyping determinants in the cardiovascular risk prediction, an exciting development that holds immense promise for the future of blood pressure research.
"We are honored to collaborate with Professors Conen and Risch and the GAPP study investigators," said Jay Shah, CMO of Aktiia. "Our collaboration represents a significant step forward in blood pressure research, and we are excited to contribute our expertise and technology to advance our understanding of health."
The long-term vision of this collaboration is to discover novel signals for blood pressure optimization. Drawing upon the extensive database of the GAPP study and Aktiia's innovative technology, the aim is to pave the way for more personalized, proactive, and patient-driven healthcare.
Aktiia's partnership with distinguished institutions and leading experts demonstrates the growing demand for the adoption of novel technologies in scientific exploration, and Aktiia continues to solidify its position as a trailblazer in the field of blood pressure technology.
Aktiia and the GAPP study investigators eagerly anticipate the discoveries and insights that will emerge from the collaboration. By combining cutting-edge technology and unparalleled expertise, this partnership will pave the way for a wholly different way to understand and optimize blood pressure.
About Aktiia SA:
Aktiia is a Swiss company specializing in cuffless blood pressure monitoring technology. Aktiia offers a clinically validated solution for continuous blood pressure measurement. Founded in 2018, Aktiia aims to revolutionize the way blood pressure is understood, making it more accessible, accurate, and convenient for individuals around the world.
For more information about Aktiia and its innovative technology, please visit www.aktiia.co
View original content:
Voltar noticias em Inglês